Variational quantum classifiers (VQCs) are often reported to perform poorly on biomedical tabular data, but such conclusions depend on the encoding circuit, the training budget, and the comparison protocol. Methods. We compared 4-qubit VQCs, a quantum-kernel SVM (QSVM), a majority-class control, and tuned classical models (on four PCA features and on all features) on Wisconsin breast cancer (n = 569), Coimbra biomarkers (n = 116), Golub leukemia gene expression (n = 72, 7,129 genes), and SEER breast-cancer registry data (n = 4,024; 15% deaths). All models were evaluated on identical blocks of 5-fold × 5-seed stratified cross-validation with preprocessing fitted on training folds, nested tuning, and Nadeau–Bengio-corrected inference with Holm correction. Trained classifiers were also evaluated on three IBM Quantum devices. Results. On the three small datasets, a VQC with the conventional two-repetition ZZ feature map was close to chance (accuracy 0.688, 0.594, 0.509), whereas a product (Z) feature map reached 0.900, 0.797, and 0.658; at matched repetition counts the Z-minus-ZZ gap was +0.12 to +0.21 and, after Holm correction, significant on Wisconsin only. More evaluations (up to 1,500) and six initializations did not close the ZZ deficit on Wisconsin. With the encoding chosen by inner cross-validation, the VQC exceeded the majority control on Wisconsin and Golub and stayed below classical models on Wisconsin and in several Golub contrasts. No statistically significant difference was detected between the encoding-selected VQC and the classical baselines on Coimbra, or between the Z-map QSVM and PCA-4 classical models; Bayesian equivalence analysis supported practical equivalence only for the QSVM on Wisconsin. On SEER the encoding mattered little: the VQC exceeded the majority control in balanced accuracy (0.548 versus 0.500) but ranked patients worse than logistic regression and random forest (ROC-AUC 0.678 versus 0.745 and 0.733). Full-feature classical models were strongest overall. On hardware (class-balanced test subsets, not natural-prevalence performance), accuracy relative to noise-free simulation changed by −0.071 to +0.048 per run (pooled ibm_fez, Wisconsin: −0.024, 95% CI −0.060 to +0.008), using 5.5 QPU-minutes. Conclusions. Under a fixed training budget, encoding choice was associated with large differences in VQC accuracy on small datasets, so single-encoding negative results should not be generalized; because the Z and ZZ maps also differ in entanglement structure, we do not attribute the gap to encoding alone. No quantum advantage was observed.
Variational quantum classifiers (VQCs) are often reported to perform poorly on biomedical tabular data, but such conclusions depend on the encoding circuit, the training budget, and the comparison protocol. Methods. We compared 4-qubit VQCs, a quantum-kernel SVM (QSVM), a majority-class control, and tuned classical models (on four PCA features and on all features) on Wisconsin breast cancer (n = 569), Coimbra biomarkers (n = 116), Golub leukemia gene expression (n = 72, 7,129 genes), and SEER breast-cancer registry data (n = 4,024; 15% deaths). All models were evaluated on identical blocks of 5-fold × 5-seed stratified cross-validation with preprocessing fitted on training folds, nested tuning, and Nadeau–Bengio-corrected inference with Holm correction. Trained classifiers were also evaluated on three IBM Quantum devices. Results. On the three small datasets, a VQC with the conventional two-repetition ZZ feature map was close to chance (accuracy 0.688, 0.594, 0.509), whereas a product (Z) feature map reached 0.900, 0.797, and 0.658; at matched repetition counts the Z-minus-ZZ gap was +0.12 to +0.21 and, after Holm correction, significant on Wisconsin only. More evaluations (up to 1,500) and six initializations did not close the ZZ deficit on Wisconsin. With the encoding chosen by inner cross-validation, the VQC exceeded the majority control on Wisconsin and Golub and stayed below classical models on Wisconsin and in several Golub contrasts. No statistically significant difference was detected between the encoding-selected VQC and the classical baselines on Coimbra, or between the Z-map QSVM and PCA-4 classical models; Bayesian equivalence analysis supported practical equivalence only for the QSVM on Wisconsin. On SEER the encoding mattered little: the VQC exceeded the majority control in balanced accuracy (0.548 versus 0.500) but ranked patients worse than logistic regression and random forest (ROC-AUC 0.678 versus 0.745 and 0.733). Full-feature classical models were strongest overall. On hardware (class-balanced test subsets, not natural-prevalence performance), accuracy relative to noise-free simulation changed by −0.071 to +0.048 per run (pooled ibm_fez, Wisconsin: −0.024, 95% CI −0.060 to +0.008), using 5.5 QPU-minutes. Conclusions. Under a fixed training budget, encoding choice was associated with large differences in VQC accuracy on small datasets, so single-encoding negative results should not be generalized; because the Z and ZZ maps also differ in entanglement structure, we do not attribute the gap to encoding alone. No quantum advantage was observed.
Variational quantum classifiers (VQCs) are often compared with classical models under unequal data partitions, tuning budgets, or statistical treatment. We benchmark a 4-qubit VQC against logistic regression, an RBF-SVM, random forest, a quantum-kernel SVM (QSVM), and a majority-class control on Breast Cancer Wisconsin (n=569), Coimbra (n=116), and Golub leukemia (n=72), using five stratified folds across five seeds (25 paired blocks per dataset), identical training-fold-fitted preprocessing, and Nadeau–Bengio corrected paired tests with Holm correction. A first arm with a frozen configuration and the common [0, π] angle encoding left the VQC at 0.563, 0.515, and 0.576 accuracy (majority 0.617, 0.552, 0.652). In a second arm, in which every model was tuned by the same inner cross-validation and the encoding scale was a tuned hyperparameter, VQC accuracy rose to 0.864, 0.616, and 0.747. On Wisconsin the VQC stayed significantly below every matched classical model (differences 0.079–0.097, Holm p≤0.006) but above the majority class; on Golub it was significantly below only the SVM (Holm p=0.016); on Coimbra no comparison was significant. A QSVM with the same feature map exceeded the VQC numerically on every dataset, and three optimizers reached the same training loss in pilot diagnostics, pointing to the encoding and the variational head rather than the optimizer. The Wisconsin arms also differ in sample size (120 versus 569). Results apply to this low-qubit, PCA-compressed, exactly simulated setting and do not indicate a quantum advantage.
Quantum Support Vector Machines (QSVMs) are frequently reported to outperform classical kernels on high-dimensional gene expression data, but such comparisons are sensitive to how the evaluation is constructed. This study compares a fidelity-based quantum kernel against six classical baselines — linear and RBF SVMs, random forest, gradient boosting, a multilayer perceptron and logistic regression — on two public breast cancer cohorts, GSE2034 (286 samples) and GSE2990 (125 samples), each described by 22,283 probes. Every preprocessing step, including imputation, gene selection, feature scaling and class rebalancing, is fitted within the training fold of a repeated stratified five-fold cross-validation, and comparisons are tested with a corrected paired t-test that accounts for the dependence between folds. Under this protocol the quantum kernel is statistically indistinguishable from every classical baseline in all four experimental conditions: no comparison reaches significance after correction, and the largest ROC-AUC gap to the strongest baseline is 0.036 (95% CI −0.073 to 0.002). Two implementation factors are shown to dominate the outcome. First, rebalancing or scaling before the train–test split inflates apparent quantum performance, because duplicated minority samples appear on both sides of the split. Second, encoding standardised expression values directly as rotation angles causes kernel concentration, which drives QSVM ROC-AUC to chance (0.501) on GSE2034; restricting the encoding to [0, π/2] restores discriminative performance. Probes selected by a supervised within-fold filter and ranked by permutation importance under the quantum kernel recover known breast cancer markers, including CD44 on GSE2034 and MMP10 on GSE2990. We conclude that reported quantum-kernel advantages on these cohorts are attributable to evaluation protocol and encoding choices rather than to the quantum kernel itself, and we provide the diagnostic used to detect kernel concentration.
In recent years, quantum machine learning (QML) has emerged as a promising approach for medical decision-making, with representative methods such as Quantum Support Vector Machines (QSVMs), Quantum Neural Networks (QNNs), and Variational Quantum Circuits (VQCs). Among these, VQCs are distinguished by their expressive capability; however, their training on small biomedical datasets often results in instability and high variance. To address this issue, we propose a heterogeneous ensemble of six shallow VQCs evaluated on the Wisconsin Breast Cancer Diagnostic (WBCD) dataset, which contains 569 diagnostic samples characterized by 30 cytological features and binary class labels differentiating benign and malignant cases. The ensemble introduces diversity through distinct feature maps, circuit architectures, and optimization strategies, using rotation gates (RX, RY, RZ) combined with entangling layers (CNOT, CZ). Model reliability is estimated from out-of-bag errors, with normalized weights calculated as the inverse of the mean squared error, and final decisions obtained via weighted soft voting. The preprocessing pipeline involves median imputation and standardization, followed by principal component analysis (PCA) to compress the 30-dimensional space into three to four principal components for quantum encoding. In our experiments, individual VQCs trained on the full dataset exhibited unstable accuracies ranging from 80% to 96% across three–four qubits, whereas the proposed ensemble achieved consistent performance of 95.71% (3 qubits) and 96.43% (4 qubits), reducing variance and matching strong classical baselines such as SVM and Random Forest. All models were implemented in PennyLane, utilizing the Lightning.qubit simulator for shot-free optimization and the default.mixed device for noise-aware evaluation, demonstrating the potential of weighted quantum ensembles for reliable biomedical classification.
A potential path forward is Quantum Machine Learning (QML), which aims to leverage quantum computing in conjunction with classical machine learning to enhance computing efficiency and the expressiveness of models. In this paper, two different quantum classifiers - Variational Quantum Classifier (VQC) and Quantum Kernel Support Vector Machine (QSVM) - are compared with three classical classifiers as baseline classifiers - Logistic Regression, Support Vector Machine (SVM), and a Multi-Layer Perceptron (MLP) - on the Breast Cancer Wisconsin dataset. The quantum circuits were created in the PennyLane framework and simulated on a classical backend. However, in terms of accuracy, classical Logistic Regression performed better with an accuracy of 97.8%, classical SVM and QSVM with an accuracy of 95.6% each, although the Quantum VQC achieved a lower accuracy of 88.9% and had a recall of 100% for the benign class, though it correctly identified only 12 of the 17 malignant cases (a malignant-class recall of approximately 70.6%). The drawback of quantum models is the higher training time; however, since the quantum circuit needs to be classically simulated, the quantum SVM took 23.29 seconds compared to less than 0.01 seconds for the classical linear models. These results indicate that for small structured datasets, classifiers based on quantum computing have not yet surpassed well-tuned classical counterparts. In some respects (e.g., benign-class recall), they perform competitively, though not on malignant-class recall, where the VQC in particular performed worse than the classical baselines, which is worth further investigation on real quantum computers.
Breast cancer is rated as one of the top leading diagnosed and deadliest cancers affecting women worldwide and causing high mortality rate among cancers. With the data-driven applications, hybrid quantum-classical machine learning models have evolved as significant alternatives for handling complex feature spaces with the growing interest in quantum computing. This paper presents a systematic comparative study of classical and quantum machine learning approaches for breast cancer classification using the Wisconsin Breast Cancer Dataset. In this architecture we have preprocessed classical feature vectors using standard normalized techniques and parallelly quantum states are mapped through data embedding techniques which relies on parameterized rotational gates. In this work we have implemented all quantum models using the Pennylane library, resulting in hybrid quantum–classical optimization on near-term quantum simulators. The comparison results in multiple classical and quantum models. In classical we have Support Vector Machine (SVM), K-Nearest Neighbors (KNN) and Convolutional Neural Networks (CNN), which are compared with the quantum-based models such as the Variational Quantum Classifier (VQC), Quantum Support Vector Machine (QSVM) and Quantum Convolutional Neural Network (QCNN). In QSVM, we have performed dimensionality reduction using Principal Component Analysis (PCA) before to quantum embedding, and quantum-generated features are used to train a classical linear SVM. The evaluation metrics results in accuracy, precision, recall, F1-score, ROC curves and confusion matrices. The classical models achieves the accuracy in the range of 94%-96%, whereas competitive performance of quantum models demonstrate depending on the embedding strategy and circuit configuration. In the implemented quantum models, the variational quantum classifier achieved the highest classification accuracy of 96.06%, surpassing other evaluated models. These results demonstrate quantum embedding combined with variational quantum circuits can effectively capture discriminative patterns in medical datasets, indicating the implementation of quantum machine learning models for breast cancer diagnosis with the present quantum simulating platforms.
Background: Breast cancer remains a leading cause of cancer-related mortality, and reliable computational decision support is increasingly viewed as a complement to expert pathological assessment rather than a replacement for it. Variational quantum classifiers (VQCs) and Quantum Support Vector Machines (QSVMs) have recently been promoted as candidate models for medical classification, yet most published comparisons rely on internal hold-out validation alone and report only a single point estimate of discrimination, omitting calibration, decision-analytic value, and explainability—three ingredients that any clinically credible model must furnish. Methods: We assembled a complete quantum–classical machine learning pipeline and evaluated it under a deliberately stringent protocol designed to expose, rather than conceal, the limitations of current Noisy Intermediate-Scale Quantum (NISQ)-era models. The analytical hypothesis was conservative and stated in advance; in light of saturated classical baselines on this benchmark, we did not anticipate a quantum advantage in raw discrimination, and we framed the study as a methodological probe rather than as a competition. Using the Wisconsin Diagnostic Breast Cancer (WDBC) dataset (n = 569) for development and an independent Wisconsin Original (WBC) cohort (n = 683) for external validation, we benchmarked five classical learners (XGBoost, LightGBM, CatBoost, RandomForest, RBF-SVM), two quantum models (an eight-qubit VQC implemented in PennyLane and a ZZ-feature-map QSVM implemented in Qiskit), and a stacked hybrid ensemble. The evaluation framework combined Optuna-driven hyperparameter optimisation, internal–external cross-validation, and external validation on the independent WBC cohort. Robustness and interpretability were then probed through circuit depth and embedding rotation ablation, depolarising noise stress tests, learning curve and feature stability analysis, decision curve analysis, and dual SHAP-based explanations covering both a direct tree-based explanation and a quantum surrogate. Reporting followed the TRIPOD + AI guideline. Results: On the internal test partition, RBF-SVM achieved the highest discrimination (AUC = 0.998), with XGBoost, LightGBM, CatBoost, the hybrid ensemble, and the VQC clustering between 0.992 and 0.996; the QSVM with a ZZ-fidelity kernel underperformed substantially (AUC = 0.727). Pairwise tests for correlated ROC curves indicated that most differences among top models were not statistically significant. On the external WBC cohort, model rankings reorganised, as RBF-SVM (AUC = 0.986, 95% CI 0.946–0.997), RandomForest (0.985, 95% CI 0.945–0.996), VQC (0.983, 95% CI 0.942–0.995), and the hybrid ensemble (0.982, 95% CI 0.941–0.995) all retained near-ceiling discrimination with extensively overlapping confidence intervals. Ablation analysis demonstrated that the choice of embedding rotation is decisive—Z-rotation embeddings collapsed VQC performance to chance levels (AUC ≈ 0.50), whereas X- and Y-rotations preserved it. Depolarising noise up to p = 0.10 had a negligible effect on the VQC, and SHAP analyses converged on worst concave points, mean concave points, and worst area as the dominant predictors across both classical and quantum models. Decision curve analysis showed positive net benefit for both classical and hybrid models across the clinically meaningful threshold range, exceeding both the treat-all and treat-none reference strategies throughout. Conclusions: In the present regime, the principal contribution of QML is not raw discrimination—modern classical learners are already at the data ceiling—but the construction of a rigorous, reproducible, externally validated, and interpretable benchmarking framework in which quantum models can be fairly compared with their classical counterparts. Because evaluation was confined to curated benchmark datasets rather than real-world clinical populations, the interpretability and net benefit findings reported here should be read as benchmark-level evidence and not as a demonstration of readiness for clinical deployment.